Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
 

This article is part of the supplement: 24th Congress of the International Association for Breast Cancer Research. Advances in human breast cancer research: preclinical models

Oral presentation

Estrogen receptor alpha-positive and negative mouse mammary tumors through somatic mutations of p53 in mammary carcinogenesis

S-CJ Lin1, K-F Lee2, AY Nikitin3, KM Bushnell4, SG Hilsenbeck5, RD Cardiff6, A Li1, K-W Kang1, SA Frank7, W-H Lee4 and EY-HP Lee1

1Department of Developmental and Cell Biology and Department of Biological Chemistry, University of California, Irvine, California, USA

2The Salk Institute for Biological Studies, La Jolla, California, USA

3Department of Biomedical Sciences, Cornell University, Ithaca, New York, USA

4Institute of Biotechnology, Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA

5Department of Medicine and Department of Molecular and Cellular Biology, Breast Center, Baylor College of Medicine, Houston, Texas, USA

6Center for Comparative Medicine, University of California, Davis, California, USA

7Department of Ecology and Evolutionary Biology, University of California, Irvine, California, USA

from 24th Congress of the International Association for Breast Cancer Research. Advances in human breast cancer research: preclinical models
Sacramento, USA. 1-5 November 2003

Breast Cancer Res 2003, 5(Suppl 1):2doi:10.1186/bcr661

Published: 31 October 2003

Oral presentation

Approximately 70% of human breast cancers are estrogen receptor alpha (ERα)-positive, but the origins of ERα-positive and ERα-negativetumors remain unclear. Most mouse models produce only ERα-negative tumors. In addition, these mouse tumors metastasize at a low rate relative to human breast tumors. We report that somatic mutations of p53 in mouse mammary epithelial cells lead to ERα-positive and ERα-negative tumors. p53 inactivation in pre-pubertal/pubertal mice, but not in adult mice, leads to the development of ERα-positive tumors, suggesting that developmental stages influence the availability of ERα-positive tumor origin cells. These tumors have a high rate of metastasis that is independent of tumor latency. An inverse relationship between the number of targeted cells and median tumor latency was also observed. The median tumor latency reaches a plateau when targeted cell numbers exceed 20%, implying the existence of saturation kinetics for breast carcinogenesis. Genetic alterations commonly observed in human breast cancer including c-myc amplification and Her2/Neu/erbB2 activation were seen in these mouse tumors. Since it is feasible to isolate ERα-positive epithelial cells from normal mammary glands and tumors, molecular mechanisms underlying ERα-positive and ERα-negative mammary carcinogenesis can be systematically addressed using this model.

Have something to say? Post a comment on this article!


© 1999-2008 BioMed Central Ltd unless otherwise stated < info@breast-cancer-research.com >   Terms and conditions